Literature DB >> 2337767

Aberrant casein kinase II in Alzheimer's disease.

D S Iimoto1, E Masliah, R DeTeresa, R D Terry, T Saitoh.   

Abstract

Abnormal protein phosphorylation has been identified in Alzheimer's disease (AD) for several proteins including a Mr 60,000 protein, a Mr 86,000 protein and a microtubule-associated protein tau. The Mr 86,000 protein is phosphorylated by protein kinase C, whereas protein kinases responsible for other aberrant phosphorylation reactions are not known. In addition to protein kinase C, another kinase, casein kinase II (CK-II), has now been shown to be aberrant in AD. The spermine-dependent CK-II activity is reduced by 84% in AD and the amount of CK-II as determined by its immunoreactivity on a Western blot is reduced by 63%. Furthermore, the distribution of CK-II in AD is altered. Although the neuronal cell body reacts well with CK-II antisera in the normal cortex, the non-tangle-bearing neurons in the AD cortex showed a 15-30% decrease in anti-CK-II immunoreactivity. The neurofibrillary tangles, on the other hand, stain very strongly with rabbit anti-CK-II and indicates that CK-II may be involved in the pathology of AD. The study of CK-II immunoreactivity for dementing diseases other than AD revealed a similar reduction, suggesting the CK-II involvement in the common process of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337767     DOI: 10.1016/0006-8993(90)90282-g

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

1.  Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.

Authors:  E Masliah; R D Terry; M Alford; R DeTeresa; L A Hansen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

2.  Predominance of CK2α over CK2α' in the mammalian brain.

Authors:  Ilaria Ceglia; Marc Flajolet; Heike Rebholz
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

3.  Sublethal doses of β-amyloid peptide abrogate DNA-dependent protein kinase activity.

Authors:  Alessio Cardinale; Mauro Racaniello; Serena Saladini; Giovanna De Chiara; Cristiana Mollinari; Maria Chiara de Stefano; Maurizio Pocchiari; Enrico Garaci; Daniela Merlo
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

4.  Co-expressions of casein kinase 2 (CK2) subunits restore the down-regulation of tubulin levels and disruption of microtubule structures caused by PrP mutants.

Authors:  Zhao-Yun Wang; Qi Shi; Shao-Bin Wang; Chan Tian; Ying Xu; Yan Guo; Cao Chen; Jin Zhang; Xiao-Ping Dong
Journal:  J Mol Neurosci       Date:  2012-07-01       Impact factor: 3.444

Review 5.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

6.  Casein kinase II alteration precedes tau accumulation in tangle formation.

Authors:  E Masliah; D S Iimoto; M Mallory; T Albright; L Hansen; T Saitoh
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

7.  Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease.

Authors:  E Masliah; M Mallory; L Hansen; M Alford; T Albright; R Terry; P Shapiro; M Sundsmo; T Saitoh
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Casein kinase 2 reverses tail-independent inactivation of kinesin-1.

Authors:  Jing Xu; Babu J N Reddy; Preetha Anand; Zhanyong Shu; Silvia Cermelli; Michelle K Mattson; Suvranta K Tripathy; Matthew T Hoss; Nikita S James; Stephen J King; Lan Huang; Lee Bardwell; Steven P Gross
Journal:  Nat Commun       Date:  2012-03-27       Impact factor: 14.919

9.  Inhibition of casein kinase 2 modulates XBP1-GRP78 arm of unfolded protein responses in cultured glial cells.

Authors:  Toru Hosoi; Kenta Korematsu; Naohiro Horie; Takahiro Suezawa; Yasunobu Okuma; Yasuyuki Nomura; Koichiro Ozawa
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells.

Authors:  L Ulloa; J Díaz-Nido; J Avila
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.